Novartis AG (XSWX:NOVN) Stock Price, Trades & News

Novartis develops and manufactures innovative drugs. Key areas of drug development are oncology, immunology, neuroscience, respiratory, and cardiovascular, renal, and metabolic. It also has an established medicines business, which includes off-patent franchises. The company sells its products globally, with the United States constituting close to one-third of total revenue.

Financial Strength

5/10

Name	Current	Vs Industry
Cash-To-Debt	0.15
Equity-to-Asset	0.33
Debt-to-Equity	1.22
Debt-to-EBITDA	2.07
Interest Coverage	14.16
Piotroski F-Score	5/9	0 1 2 3 4 5 6 7 8 9
Altman Z-Score	3.66	Distress Grey Safe
Beneish M-Score	-2.7	Manipulator Not Manipulator
WACC vs ROIC		WACC ROIC

Growth Rank

7/10

	Name	Current	Vs Industry		Vs History
	3-Year Revenue Growth Rate	7.8
	3-Year EBITDA Growth Rate	14.3
	3-Year EPS without NRI Growth Rate	30.1
	3-Year FCF Growth Rate	6.9
	3-Year Book Growth Rate	-9.6
	Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank	6.31
	Future 3-5Y Total Revenue Growth Rate Estimate	5.43

Momentum Rank

10/10

	Name	Current	Vs Industry		Vs History
	5-Day RSI	81.66
	9-Day RSI	73.15
	14-Day RSI	67.86
	3-1 Month Momentum %	-0.9
	6-1 Month Momentum %	7.57
	12-1 Month Momentum %	23.35

Liquidity Ratio

	Name	Current	Vs Industry		Vs History
	Current Ratio	0.85
	Quick Ratio	0.65
	Cash Ratio	0.22
	Days Inventory	166.33
	Days Sales Outstanding	58.98
	Days Payable	118.23

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History
	Dividend Yield %	2.93
	Dividend Payout Ratio	0.65
	3-Year Dividend Growth Rate	0.4
	Forward Dividend Yield %	2.93
	5-Year Yield-on-Cost %	3.4
	3-Year Average Share Buyback Ratio	3.4
	Shareholder Yield %	4.82

Profitability Rank

7/10

	Name	Current	Vs Industry		Vs History
	Gross Margin %	75.39
	Operating Margin %	30.44
	Net Margin %	23.94
	EBITDA Margin %	39.6
	FCF Margin %	28.3
	OCF Margin %	33.97
	ROE %	31.74
	ROA %	12.28
	ROIC %	13.88
	3-Year ROIIC %	-44.39
	ROC (Joel Greenblatt) %	140.21
	ROCE %	21.58
	Years of Profitability over Past 10-Year	10
	Moat Score	8
	Tariff Resilience Score	8

GF Value Rank

6/10

	Name	Current	Vs Industry		Vs History
	PE Ratio	22.64
	Forward PE Ratio	18.29
	PE Ratio without NRI	22.64
	Shiller PE Ratio	24.36
	Price-to-Owner-Earnings	17.3
	PEG Ratio	9.06
	PS Ratio	5.42
	PB Ratio	7.95
	Price-to-Free-Cash-Flow	19.19
	Price-to-Operating-Cash-Flow	15.98
	EV-to-EBIT	20.15
	EV-to-Forward-EBIT	16.59
	EV-to-EBITDA	15.3
	EV-to-Forward-EBITDA	14.57
	EV-to-Revenue	6.06
	EV-to-Forward-Revenue	5.83
	EV-to-FCF	21.41
	Price-to-GF-Value	1.23
	Price-to-Projected-FCF	1.79
	Price-to-Median-PS-Value	1.33
	Earnings Yield (Greenblatt) %	4.96
	FCF Yield %	5.31
	Forward Rate of Return (Yacktman) %	5.31

GF Value™: CHF103.02

XSWX:NOVN

Warning Signs

Warning! GuruFocus detected 7 Medium warning signs with NOVN. Try a 7-Day Free Trial to check it out.

Novartis AG Filings

10-K10-QForm 4Others

	Filing Date	Document Date	Form
No Filing Data

Novartis AG Stock Events

Financials Calendars

Event	Date	Price (CHF)
Third quarter earnings conference call for 2026	2026-10-27	In 121 days
Third quarter earnings results for 2026	2026-10-27	In 121 days
Second quarter earnings conference call for 2026	2026-07-21	In 23 days
Second quarter earnings results for 2026	2026-07-21	In 23 days
First quarter earnings conference call for 2026	2026-04-28 14:00	114.08 (+0.49%)
First quarter earnings results for 2026	2026-04-28	114.08 (+0.49%)
CHF 3.700000 Cash Dividend	2026-03-10	125.30 (+3.09%)
General meeting for 2026	2026-03-06 10:00	124.82 (-2.29%)
Fourth quarter earnings conference call for 2025	2026-02-04 14:00	116.88 (-0.32%)
Annual report for 2025	2026-02-04	116.88 (-0.32%)

Show

Entries

Press Release

	Subject	Date
	Novartis receives FDA approval for Rhapsido® (remibrutinib), the only oral, targeted BTKi treatment for chronic spontaneous urticaria (CSU)	2025-09-30
	Argo Biopharma Announces Multi-Asset License and Option Agreements with Novartis for Novel Molecules for Cardiovascular Diseases	2025-09-03
	Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren's disease	2025-08-11
	Novartis twice-yearly* Leqvio® (inclisiran) receives FDA approval for new indication enabling first-line use	2025-07-31
	Novartis provides update on Phase III GCAptAIN study of Cosentyx® in giant cell arteritis (GCA)	2025-07-03
	Novartis receives FDA accelerated approval for Vanrafia® (atrasentan), the first and only selective endothelin A receptor antagonist for proteinuria reduction in primary IgA nephropathy (IgAN)	2025-04-02
	Novartis receives third FDA approval for oral Fabhalta® (iptacopan) - the first and only treatment approved in C3 glomerulopathy (C3G)	2025-03-20
	Novartis data presentations at AAAAI and AAD underscore commitment to advancing treatment of hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU)	2025-02-28
	Ratio Enters License and Collaboration Agreement with Novartis for SSTR2-targeting Radiotherapeutic Candidate	2024-11-18
	Novartis receives positive CHMP opinion for Kisqali® to help reduce risk of recurrence in people with HR+/HER2- early breast cancer	2024-10-18

10/Page

Articles on Novartis AG

No articles.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.

Novartis AG - Registered Shares

Business Description